Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil.
Neurological Rehabilitation Unit, Sarah Network of Rehabilitation Hospitals, Brasília 70335-901, Brazil.
Int J Mol Sci. 2024 Aug 17;25(16):8971. doi: 10.3390/ijms25168971.
Parkinson's disease (PD) is the second most common neurodegenerative disease globally. Current drugs only alleviate symptoms without halting disease progression, making rodent models essential for researching new therapies and understanding the disease better. However, selecting the right model is challenging due to the numerous models and protocols available. Key factors in model selection include construct, face, and predictive validity. Construct validity ensures the model replicates pathological changes seen in human PD, focusing on dopaminergic neurodegeneration and a-synuclein aggregation. Face validity ensures the model's symptoms mirror those in humans, primarily reproducing motor and non-motor symptoms. Predictive validity assesses if treatment responses in animals will reflect those in humans, typically involving classical pharmacotherapies and surgical procedures. This review highlights the primary characteristics of PD and how these characteristics are validated experimentally according to the three criteria. Additionally, it serves as a valuable tool for researchers in selecting the most appropriate animal model based on established validation criteria.
帕金森病（PD）是全球第二常见的神经退行性疾病。目前的药物只能缓解症状，无法阻止疾病进展，因此啮齿动物模型对于研究新疗法和更好地了解疾病至关重要。然而，由于有众多的模型和方案可供选择，因此选择合适的模型具有挑战性。模型选择的关键因素包括构建、表象和预测有效性。构建有效性确保模型复制了人类 PD 中观察到的病理变化，重点关注多巴胺能神经退行性变和α-突触核蛋白聚集。表象有效性确保模型的症状与人类的症状相似，主要是复制运动和非运动症状。预测有效性评估动物治疗反应是否会反映人类的治疗反应，通常涉及经典的药物治疗和手术程序。这篇综述强调了 PD 的主要特征，以及根据这三个标准如何通过实验验证这些特征。此外，它为研究人员根据既定的验证标准选择最合适的动物模型提供了有价值的工具。
